INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $358,218 | +131.1% | 26,673 | +137.8% | 0.12% | +51.9% |
| Q2 2022 | $155,000 | -52.5% | 11,216 | +173.6% | 0.08% | -64.5% |
| Q2 2019 | $326,000 | -71.8% | 4,099 | -79.3% | 0.22% | -35.8% |
| Q4 2017 | $1,156,000 | +123.6% | 19,786 | +122.3% | 0.34% | +131.5% |
| Q3 2017 | $517,000 | -28.8% | 8,900 | +48.3% | 0.15% | -41.8% |
| Q2 2017 | $726,000 | +64.6% | 6,000 | +53.8% | 0.25% | +39.4% |
| Q1 2017 | $441,000 | – | 3,900 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |